Stemline Therapeutics, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics. ELZONRISď (tagraxofusp), a targeted therapy directed to CD123, is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with blastic plasmacytoid dendritic cell neoplasm (BPDCN). In Europe, a marketing authorization application (MAA) is under review by the European Medicines Agency (EMA). ELZONRIS is also being evaluated in clinical trials in additional indications including chronic myelomonocytic leukemia (CMML), myelofibrosis (MF) and acute myeloid leukemia (AML). Additional pipeline candidates include: felezonexor (SL-801) (XPO1 inhibitor; Phase 1 in advanced solid tumor patients ongoing), SL-1001 (novel RET kinase inhibitor, IND-enabling studies ongoing), SL-701 (immunotherapeutic; Phase 2 in glioblastoma patients completed), and SL-901 (novel kinase inhibitor; prior abbreviated European Phase 1, IND-enabling studies ongoing). Source
No articles found.
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses o...
Aeolus Pharmaceuticals, Inc. is a biopharmaceut...
At Achillion, we are driven to transform the lives of patients and families affect...
At Achillion, we are driven to transform the li...
Cerecor is an integrated biopharmaceutical company developing innovative therapies...
Cerecor is an integrated biopharmaceutical comp...
Aerie Pharmaceuticals is an ophthalmic pharmaceutical company focused on the disco...
Aerie Pharmaceuticals is an ophthalmic pharmace...
Gamida Cell is a clinical-stage biopharmaceutical company committed to developing ...
Gamida Cell is a clinical-stage biopharmaceutic...
OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...
OncoSec Medical Incorporated is a clinical-stag...
Join the National Investor Network and get the latest information with your interests in mind.